CYSTEINE HYDROCHLORIDE (cysteine hydrochloride) by Pfizer is enzyme, cystathionase, via the trans-sulfuration pathway, and serves as a precursor substrate for both glutathione and taurine. First approved in 1986.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Cysteine Hydrochloride is a parenteral nutrition supplement providing cysteine to neonates who cannot synthesize adequate quantities due to deficient cystathionase activity. It works as a precursor substrate for glutathione and taurine synthesis via the trans-sulfuration pathway. This injectable amino acid is essential for neonatal development and metabolic function.
Approaching loss of exclusivity signals team right-sizing and focus shifting toward generic defense or product lifecycle extension strategies.
enzyme, cystathionase, via the trans-sulfuration pathway, and serves as a precursor substrate for both glutathione and taurine. Cysteine hydrochloride injection, USP provides cysteine to the systemic circulation of neonates who require parenteral nutrition and cannot synthesize adequate quantities…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pfizer is hiring 1 role related to this product
Worked on CYSTEINE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Cysteine Hydrochloride offers a mature product management experience in a specialized niche market with limited growth headroom. Career progression is best suited for professionals focused on operational excellence, regulatory compliance, and managed market transitions rather than expansion-phase innovation.
1 open roles linked to this drug
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo